Delivery Order SPE2DB24D2100-SPE2DB25FBGBG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,386.63 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management treatment, representing a specialized pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,661.30 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $2,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The Defense Logistics Agency awarded a delivery order valued at $2,971.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.87 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 7, 2025. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger pharmaceutical supply agreement, represents a competitive award with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a delivery order valued at $6,005.38 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen injectors on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management in adults with...
- The Defense Logistics Agency awarded a delivery order valued at $9,356.24 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 11, 2025, with completion by August 12, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $4,964.46 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment, reflecting the Defense...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGBGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,508.40 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, reflecting the federal government's ongoing pharmaceutical procurement needs for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.999 billion comprehensive global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp maintains a substantial portfolio of federal medical supply contracts covering a wide range of therapeutic domains including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialty medical supplies. The contract demonstrates the company's critical role in supporting the Defense Health Agency and other federal healthcare systems through competitively awarded delivery orders featuring firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/27/25 |